NCCN guidelines® Insights: Non-small cell lung cancer, version 4.2016 Featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 14, Issue 3, 2016, Pages 255-264

  Ettinger, David S ^a   Wood, Douglas E ^b   Akerley, Wallace ^c   Bazhenova, Lyudmila A ^d   Borghaei, Hossein ^e   Camidge, David Ross ^f   Cheney, Richard T ^g   Chirieac, Lucian R ^h   D'Amico, Thomas A ⁱ   Dilling, Thomas J ^j   Chris Dobelbower, M ^k   Govindan, Ramaswamy ^l   Hennon, Mark ^g   Horn, Leora ^m   Jahan, Thierry M ⁿ   Komaki, Ritsuko ^o   Lackner, Rudy P ^p   Lanuti, Michael ^q   Lilenbaum, Rogerio ^r   Lin, Jules ^s   Loo, Billy W ^t   Martins, Renato ^b   Otterson, Gregory A ^u   Patel, Jyoti D ^v   Pisters, Katherine M ^o   Reckamp, Karen ^w   Riely, Gregory J ^x   Schild, Steven E ^y   Shapiro, Theresa A ^a   Sharma, Neelesh ^z   Stevenson, James ^z   Swanson, Scott J ^h   Tauer, Kurt ^aa   Yang, Stephen C ^a   Gregory, Kristina ^ab   Hughes, Miranda ^ab   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f University of Colorado Cancer Center   (United States)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

^h Dana Farber/Brigham and Women's Cancer Center   (United States)

ⁱ DUKE CANCER INSTITUTE   (United States)

^j H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l BARNES JEWISH HOSPITAL   (United States)

^m VANDERBILT INGRAM CANCER CENTER   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^p UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^q MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^r YALE CANCER CENTER   (United States)

^s UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^t STANFORD CANCER INSTITUTE   (United States)

^u OHIO STATE UNIVERSITY   (United States)

^v NORTHWESTERN UNIVERSITY   (United States)

^w CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^x MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^y MAYO CLINIC CANCER CENTER   (United States)

^z UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^aa UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^ab National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; NIVOLUMAB; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TAXOID;

CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CONTINUING EDUCATION; HISTOLOGY; HUMAN; LUNG NONSQUAMOUS CELL CARCINOMA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL RATE; TREATMENT RESPONSE; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; IMMUNOTHERAPY; LUNG NEOPLASMS; PATHOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LUNG NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SURVIVAL RATE; TAXOIDS;

EID: 84961575658     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2016.0031     Document Type: Review

References (23)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2012, based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Bethesda, MD: National Cancer Institute; 2015. Available at: http://seer.cancer.gov/csr/1975-2012/. Accessed February 8, 2016.
3. SEER Cancer Statistics Factsheets: Lung and Bronchus Cancer. Bethesda, MD: National Cancer Institute Available at http://seer.cancer.gov/statfacts/html/lungb.html Accessed February 8 2016.
4. Ettinger DS, Cox JD, Ginsberg RJ, et al. NCCN Non-Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park) 1996;10:81-111.
5. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-Term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015;33:2004-2012.
6. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-135.
7. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-Arm trial. Lancet Oncol 2015;16:257-265.
8. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-2028.
9. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-1639.
10. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial [published online ahead of print December 18, 2015]. Lancet, doi: 10.1016/S0140-6736(15)01281-7.
11. Brahmer JR, Hammers H, Lipson EJ. Nivolumab: Targeting PD-1 to bolster antitumor immunity. Future Oncol 2015;11:1307-1326.
12. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974-1982.
13. Ribas A. Releasing the brakes on cancer immunotherapy. N Engl J Med 2015;373:1490-1492.
14. Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015;33:3541-3543.
15. Bustamante Alvarez JG, Gonzalez-Cao M, Karachaliou N, et al. Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med 2015;12:209-222.
16. Vansteenkiste J, Fehrenbacher L, Spira AI, et al. Atezolizumab monotherapy vs docetaxel in 2L/3L non-small cell lung cancer: primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR) [abstract]. Available at: http://www.europeancancercongress. org/Scientific-Programme/Abstract-search?abstractid=23093. Accessed February 8, 2016.
17. Besse B, Johnson ML, Janne PA, et al. Phase II trial (BIRCH) of atezolizumab as first-line or subsequent therapy for advanced PD-L1-selected non-small cell lung cancer (NSCLC) [abstract]. Available at: http://www.europeancancercongress.org/Scientific-Programme/Abstract-search?abstractid=23106. Accessed February 8, 2016.
18. Scarpace SL. Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies. Drugs Context 2015;4:212289.
19. Sgambato A, Casaluce F, Sacco PC, et al. Anti PD-1 and PDL-1 immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC): A review on toxicity profile and its management [published online ahead of print September 27, 2015]. Curr Drug Saf, in press.
20. Chapman PB, DAngelo SP, Wolchok JD. Rapid eradication of a bulky melanoma mass with one dose of immunotherapy. N Engl J Med 2015;372:2073-2074.
21. Kyi C, Hellmann MD, Wolchok JD, et al. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer 2014;2:19.
22. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book 2015;35:76-83.
23. Khoja L, Butler MO, Kang SP, et al. Pembrolizumab. J Immunother Cancer 2015;3:36.